Investigational Drug for Facioscapulohumeral Muscular Dystrophy Gets Orphan Drug Designation
<a href="https://pixabay.com/users/simple_tunchi0/">simple_tunchi0</a> / Pixabay

Investigational Drug for Facioscapulohumeral Muscular Dystrophy Gets Orphan Drug Designation

According to a story from BioSpace, the biopharmaceutical company Acceleron Pharma, which develops TGF-beta based treatments for rare and serious illnesses, recently announced that the U.S. Food and Drug Administration…

Continue Reading
Close Menu